Page 170 - Haematologica June

1072
J. Celay et al.
Fundación Arnal Planelles, and Roche Spain (Hemato-Oncology award 2014) (to JAM-C, JJL and JFM); Worldwide Cancer Research (WCR15-1322), ISCIII/FIS PI16/00581, and ISCIII/FIS-CIBERONC (to JAM-C); Ministerio de Educación y Ciencia SAF2013-42772-R and SAF2016-78568-R and
Fundación Bancaria La Caixa-Hepacare Project, Ministerio de Educación y Ciencia SAF2013-42772-R and SAF2016-78568-R (to JJL), and Ministerio de Economia y Competitividad by the Torres-Quevedo subprogram PTQ-14-07320 (to IdM). JC is a Juan de la Cierva post-doctoral fellow.
References
1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375- 2390.
2. Shaffer AL, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30(1):565-610.
3. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma: treatment approaches in the molecular era. Nat Rev Clin Oncol. 2013;11(1):12-23.
4. Nowakowski GS, Blum KA, Kahl BS, et al. Beyond RCHOP: A blueprint for diffuse large B cell lymphoma research. J Natl Cancer Inst. 2016;108(12):djw257.
5. Pavanello F, Zucca E, Ghielmini M. Rituximab: 13 open questions after 20 years of clinical use. Cancer Treat Rev. 2017;53:38-46.
6. Goodman A, Patel SP, Kurzrock R. PD-1– PD-L1 immune-checkpoint blockade in B- cell lymphomas. Nat Rev Clin Oncol. 2016;14(4):203-220.
7. Zou W. Regulatory T cells, tumour immu- nity and immunotherapy. Nat Rev Immunol. 2006;6(4):295-307.
8. Lozano T, Casares N, Lasarte JJ. Searching for the Achilles Heel of FOXP3. Front Oncol. 2013;3:294.
9. Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and con- ventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017; 17(5):286-301.
10. Feske S, Skolnik EY, Prakriya M. Ion chan- nels and transporters in lymphocyte func- tion and immunity. Nat Rev Immunol. 2012;12(7):532-547.
11. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev. 2009;231(1):59-87.
12. King LB, Freedman BD. B-lymphocyte cal- cium inFlux. Immunol Rev. 2009; 231(1):265-277.
13. De Vito P. The sodium/hydrogen exchang- er: A possible mediator of immunity. Cell Immunol. 2006;240(2):69–85.
14. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671-677.
15. Parks SK, Chiche J, Pouyssegur J. pH con- trol mechanisms of tumor survival and growth. J Cell Physiol. 2011;226(2):299- 308.
16. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer. 2005;5(10):786-795.
17. Lang F, Huber SM, Szabo I, Gulbins E. Plasma membrane ion channels in suicidal cell death. Arch Biochem Biophys. 2007;462(2):189-194.
18. Mendler AN, Hu B, Prinz PU, Kreutz M, Gottfried E, Noessner E. Tumor lactic aci- dosis suppresses CTL function by inhibi- tion of p38 and JNK/c-Jun activation. Int J cancer. 2012;131(3):633–640.
19. Nakagawa Y, Negishi Y, Shimizu M, Takahashi M, Ichikawa M, Takahashi H. Effects of extracellular pH and hypoxia on the function and development of antigen- specific cytotoxic T lymphocytes. Immunol Lett. 2015;167(2):72-86.
20. Rich IN, Worthington-White D, Garden O a, Musk P. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood. 2000;95(4):1427-1434.
21. Marches R, Vitetta ES, Uhr JW. A role for intracellular pH in membrane IgM-mediat- ed cell death of human B lymphomas. Proc Natl Acad Sci USA. 2001;98(6):3434-3439.
22. Yue Loo S, Ker Xing Chang M, Sui Huay Chua C, Prem Kumar A, Pervaiz S, Veronique Clement M. NHE-1: a promising target for novel anti-cancer therapeutics. Curr Pharm Des. 2012;18(10):1372-1382.
23. Parks SK, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013;13(9):611-623.
24. Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543-560.
25. Alper SL. Molecular physiology and genet- ics of Na+-independent SLC4 anion exchangers. J Exp Biol. 2009;212(11):1672- 1683.
26. César-Razquin A, Snijder B, Frappier- Brinton T, et al. A call for systematic research on solute carriers. Cell. 2015; 162(3):478-487.
27. Alper SL. Molecular physiology of SLC4 anion exchangers. Exp Physiol. 2006; 91(1):153-161.
thetic peptide from transforming growth factor type III receptor inhibits liver fibro- genesis in rats with carbon tetrachloride liver injury. Cytokine. 2003;22(1–2):12–20.
36. Borrás-Cuesta F, Golvano J, Sarobe P, et al. Insights on the amino acid side-chain inter- actions of a synthetic T-cell determinant. Biologicals. 1991;19(3):187-190.
37. Maupetit J, Derreumaux P, Tufféry P. A fast method for large-scale de novo peptide and miniprotein structure prediction. J Comput Chem. 2010;31(4):72-738.
38. Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tufféry P. PEP-FOLD: An updated de novo structure prediction serv- er for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 2012;40(W1):W288-293.
39. Lozano T, Villanueva L, Durántez M, et al. Inhibition of FOXP3/NFAT interaction enhances T Cell function after TCR stimu- lation. J Immunol. 2015;195(7):3180-3189.
40. Rodríguez-Ortigosa CM, Celay J, Olivas I, et al. A GAPDH-mediated trans-nitrosyla- tion pathway is required for feedback inhi- bition of bile salt synthesis in rat liver. Gastroenterology. 2014;147(5):1084–1093.
41. Beltran E, Fresquet V, Martinez-Useros J, et al. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lym- phoma. Proc Natl Acad Sci USA. 2011; 108(30):12461-12466.
42. Sagardoy A, Martinez-Ferrandis JI, Roa S, et al. Downregulation of FOXP1 is required during germinal center B-cell function. Blood. 2013;121(21):4311-4320.
43. Lozano T, Soldevilla MM, Casares N, et al. Targeting inhibition of Foxp3 by a CD28 2’-Fluro oligonucleotide aptamer conjugat- ed to P60-peptide enhances active cancer immunotherapy. Biomaterials. 2016;91:73-
28. Romero MF, Chen AP, Parker MD, Boron
WF. The SLC4 family of bicarbonate
(HCO3-) transporters. Mol Aspects Med. 2013;34(2–3):159-182. 80.
29. Uriarte I, Banales JM, aez E, Arenas F, et al. Bicarbonate secretion of mouse cholangio- cytes involves Na-HCO3 cotransport in addition to Na-independent Cl/HCO3 exchange. Hepatology. 2010;51(3):891–902.
30. Medina JF, Recalde S, Prieto J, et al. Anion exchanger 2 is essential for spermiogenesis in mice. Proc Natl Acad Sci USA. 2003;100(26):15847-15852.
31. Salas JT, Banales JM, Sarvide S, et al. Ae2a,b-deficient mice develop antimito- chondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology. 2008;134(5):1482-1493.
32. Concepcion AR, Salas JT, Sarvide S, et al. Anion exchanger 2 is critical for CD8+ T cells to maintain pHi homeostasis and modulate immune responses. Eur J Immunol. 2014;44(5):1341-1351.
33. Concepcion AR, Salas JT, Sáez E, et al. CD8+ T cells undergo activation and pro- grammed death-1 repression in the liver of aged Ae2a,b –/– mice favoring autoim- mune cholangitis. Oncotarget. 2015; 6(30):28588v28606.
34. Romero MF, Fulton CM, Boron WF. The SLC4 family of HCO 3 - transporters. Pflugers Arch. 2004;447(5):495-509.
35. Ezquerro IJ, Lasarte JJ, Dotor J, et al. A syn-
44. Gil-Guerrero L, Dotor J, Huibregtse IL, et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol. 2008;181(1):126-135.
45. Thomas JA, Buchsbaum RN, Zimniak A, Racker E. Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectro- scopic probes generated in situ. Biochemistry. 1979;18(11):2210-2218.
46. Musgrove E, Rugg C, Hedley D. Flow cyto- metric measurement of cytoplasmic pH: A critical evaluation of available fluo- rochromes. Cytometry. 1986;7(4):347–355.
47. Robles EF, Mena-Varas M, Barrio L, et al. Homeobox NKX2-3 promotes marginal- zone lymphomagenesis by activating B-cell receptor signalling and shaping lympho- cyte dynamics. Nat Commun. 2016;7:11889.
48. Wolke C, Tadje J, Bukowska A, et al. Assigning the phenotype of a natural regu- latory T-cell to the human T-cell line, KARPAS-299. Int J Mol Med. 2006;17(2):275-278.
49. Bhat A, Roberts LR, Dwyer JJ. Lead discov- ery and optimization strategies for peptide macrocycles. Eur J Med Chem. 2015; 94:471-479.
haematologica | 2018; 103(6)